STAT44%
Readout LOUD podcast: FDA commissioner candidates 6%
By Allison DeAngelis25% Elaine Chen14% Adam Feuerstein43%
7/9/2026, 8:07:54 PM
BS Summary: This article contains 10 faulty reasoning types, including Red Herring, Framing Effect, and Negativity Bias, with Attempt to Sell a Product or Service as the most egregious example at 16.6% saturation with 77 hits. Analysis detected 304 faulty-reasoning hits from 465 analyzed words, generating a BS Score of 21.6% and a BS Rank of 6% (20,698 of 21,886 articles). This article is better (less manipulative) than 94.60% of the article peer group.
Whistleblower takes on health insurance and FDA commissioner candidates
By Allison DeAngelis , Elaine Chen , and Adam Feuerstein
Allison covers what hot startups are getting up to, and who’s financing them.
She is also co-host of the weekly biotech podcast, “ The Readout Loud .”
You can reach Allison on Signal at AllisonDeAngelis.01.
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector.
She co-writes The Readout newsletter , and co-hosts STAT’s weekly biotech podcast, The Readout Loud .
You can reach Elaine on Signal at elaineywchen.70.
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology.
He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard.
You can reach Adam on Signal at stataf.54.
Why does getting family health insurance through a job cost as much as buying a new car?
How did a whistleblower take on an insurance contractor?
And who might be the new Food and Drug Administration commissioner?
We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s weekly biotech podcast.
STAT reporter Bob Herman joins us to discuss his new series, “Out of Pocket, Out of Reach,” which dives into how soaring costs for health insurance are hurting Americans and small business owners.
We also speak with Chris Deacon, who filed a whistleblower lawsuit after spotting how an insurer may have violated contracts to provide health benefits for New Jersey’s state workers.
We also discuss the latest news in life sciences, including Anthropic’s push into drug development and Vertex’s largest-ever acquisition.
To read the “Out of Pocket, Out of Reach” series, go here ; for more information on AstraZeneca and Ionis Pharma’s trial failure, go here ; for more information on the FDA commissioner candidates, go here ; to read about Vertex’s acquisition of Crinetics, go here ; and to read about Claude Science, go here .
Be sure to sign up for “The Readout LOUD” on Apple Podcasts , Spotify , or wherever you get your podcasts.
AstraZeneca , biotechnology , FDA , health care costs , Health insurance , Vertex
Submit a correction request Reprints
Biotech Startups and Venture Capital Reporter
National Biotech Reporter
Senior Writer, Biotech
The mysterious case of Eli Lilly’s obesity drug
New hope in treating Huntington’s disease and a report card on RFK Jr.’s promises
STAT Plus: An obesity drug deep-dive, and peptides move mainstream
What RevMed’s pancreatic cancer drug meant for one patient
STAT Plus: Biotech veteran Jeremy Levin on why the industry’s future is secure, but American leadership is at risk
Speakers
5speakers37%attributed speech291writer words
Voice mapSelect a segment to jump to its words
Selected voice
100%flagged-word coverageBob Herman
33 attributed words19% of attributed speech50% writer coverage
Attribution is sentence-level. Pattern percentages are calculated only from words assigned to that voice.
Loading…
Loading…
Loading…
Loading…
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.